Neurological injury is a frequent and important complication of coronary artery bypass grafting (CABG). Several risk factors for this type of sequela have been identified, among them aortic arch atherosclerosis. Our previous study indicated that atherosclerotic burden in coronary arteries may likewise predict postoperative neurological complications (Pawliszak et al., 2016b) . We assessed the severity of this condition by using the SYNTAX score calculator. However, diagnosing angiographic three-vessel coronary artery disease (3VD) could be an even simpler method of achieving this goal.
Postoperative neurological injury is a diagnostic challenge. Comprehensive evaluation of its various clinical manifestations requires time, specialized equipment, and qualified personnel, and therefore is never performed outside of a research setting. Consequently, clinicians could greatly benefit from devising an indicator of brain damage that is sensitive, specific only to brain tissue, and easily measurable in patients' blood shortly after surgery. Such requirements may be met by the three following state-ofthe-art biochemical markers: glial fibrillary acidic protein (GFAP), neuroserpin (NSP), and phosphorylated axonal neurofilament subunit H (PNFH). They were identified on the basis of recently published pilot studies and have never before been used in cardiac surgery (Rodríguez-González et al., 2011; Singh et al., 2011; Luger et al., 2017) . The aim of this study was to assess the correlation between 3VD and changes in levels of these three novel biochemical brain injury markers following off-pump CABG.
This prospective observational cohort study was approved by the All surgical interventions were performed by the same operator and under the same anesthetic protocol. Each procedure was carried out through a median sternotomy using an Octopus coronary stabilizer (Medtronic Inc., MN, USA) for distal anastomosis and a side-biting clamp on the aorta for proximal anastomosis. Choice of graft vessels was left to the surgeon's discretion. Blood samples were collected just before the first incision of the skin and just after stitching of the skin. They were drawn from the ulnar vein into 5-ml tubes containing a clot activator and gel. Serum was obtained by blood centrifugation (2500g for 20 min at room temperature), divided into aliquots, and stored at −80 °C until analyzed. Levels of GFAP, NSP, and PNFH were determined using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions (BioVendor-Laboratorni medicina a.s., Brno, Czech Republic). The inter-and intra-assay coefficients of variation for all tests were ≤11%.
All statistical analyses were performed using Statistica ® 13.1 (Dell Software Inc., Round Rock, TX, USA). Data were assessed for normality using the Shapiro-Wilk test, and homogeneity of variance was checked using the Brown-Forsythe test. Since our data did not meet the assumption of parametric statistics, the Mann-Whitney U test was employed for independent samples and the Wilcoxon test for paired samples. For categorical data analysis, Fisher's exact test was used. All correlations were analyzed with Spearman's nonparametric correlation coefficient. A P value of less than 0.05 was considered statistically significant.
After eligibility assessment, 35 consecutive patients were included in the study. A 3VD group consisting of 26 patients was compared with a non-3VD group of 9 patients. Participants' pre-, intra-, and postoperative characteristics (Table 1) did not differ between the groups. Postoperatively, patients from the 3VD group presented statistically significant changes in the levels of GFAP, NSP, and PNFH, while patients from the non-3VD group presented a statistically significant change only in the level of NSP (Fig. 1) . We did not observe any significant differences in the preoperative levels of GFAP, NSP, or PNFH between the sex and comorbidity groups (Figs. S1-S3 ). Correlations between other clinical parameters and the preoperative levels of the biochemical brain injury markers are presented in Table S1 . The main finding of this pilot study was that there was a greater change in postoperative levels of the biochemical brain injury markers after off-pump CABG in patients with 3VD than in patients without 3VD. Presumably, this is because a greater atherosclerotic burden in coronary arteries predicts stenosis in other vascular zones that promote postoperative brain damage, especially the ascending aorta. Its surgical manipulation was shown to markedly increase the risk of various neurological complications (Szwed et al., 2014 (Szwed et al., , 2017 Pawliszak et al., 2016a) . All biochemical brain injury markers introduced for the first time in the current study showed a great value in this clinical setting by providing tangible results in small groups of patients. For this reason, they deserve a thorough evaluation in further research. The fact that only levels of NSP changed significantly in patients both with and without 3VD may seem unexpected, especially considering that NSP and PNFH are derived from the same type of brain cells (neurons). However, unlike PNFH, NSP is not phosphorylated which makes it susceptible to proteolytic breakdown in blood, which may lower its diagnostic potential. High preoperative levels of GFAP were also unexpected. Nevertheless, biological variability in GFAP levels is very high even among healthy individuals, and depends on both the kind of material tested and the test methodology (Table S2) .
The strengths of this study include its innovative nature and cutting-edge biochemical methodology, as well as its prospective design and consistent cohort of patients operated on by a single surgeon. At the same time, we acknowledge that due to its preliminary nature, the number of participants was small and blood samples were collected at only two time points. Summing up, patients with 3VD undergoing elective off-pump CABG present a greater change in postoperative levels of biochemical brain injury markers than patients without 3VD. This observation may help clinicians to optimize risk evaluation and the clinical management of patients undergoing off-pump CABG. Furthermore, the pioneering biochemical data yielded by this study provide both encouragement and a reference point for future research using GFAP, NSP, and PNFH.
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